REPLICATE® System | Updates

By Lea Ellermeier & Rüdger Rubbert

NDI comes up with a positive result in the first eight days of the campaign


Dear Companists,

We would like to sincerely thank you for your support and the congratulations you gave us! With your help, we managed to surpass the €250,000 threshold in just 8 days. Since we have already received many questions, we would like to release our first update.


Co-investment target reached

The co-investment contracts were signed by lead investor GUB with the launch of the Companisto campaign. We are pleased to announce that the target sum of 1 million euro has now been reached. The renewed investment from the VC company GUB emphasizes the excellent business performance as well as the huge potential of the REPLICATE System and NDI AG as a company. Align Technology (NASDAQ: ALGN) has already shown that a disruptive product in dental medicine can quickly become successful with a current stock market valuation of more than 13 billion US dollars.


A)Frequently asked questions about the investment

A1 Why equity-based crowdfunding?

As a high-tech company in the medical industry, with an innovative market-ready product in a billion-dollar market, it is rather unusual to use an equity-based crowdfunding platform. NDI AG had been privately financed until recently and is now open to public funding for the following reasons:

  • The REPLICATE System is a product that everyone understands and can affect everyone
  • In the medium term, we are planning on going public and are interested in the reactions of a broad audience
  • The media impact of an equity-based crowdfunding campaign gives us access to many new potential end users (dentists and patients)
  • We gain with each Companist an important, irreplaceable multiplier


A2 Why such a high rating? Is this reflected in the current sales figures?

We have validated the REPLICATE System over the last 4.5 years with a group of dentists and specialists. Several studies have been conducted in which REPLICATE teeth have been provided free of charge. The introduction of a new medical device is extremely cost-intensive, which is why sales figures do not accurately represent actual developments.

In addition, start-ups are never evaluated according to current sales figures. Rather, the company valuation reflects a company’s potential market value. This is reflected on the stock exchange by the share price, in the case of start-ups, by the price attached to issuing new shares. In the current round of financing, the experienced VC company GUB has invested 1 million euro with a valuation of 45 million euro. We regard the valuation as fair, in view of the present company development as well as the huge market potential. To date, 14 million euro has been invested in NDI AG. As a high-tech start-up in the medical industry, a comparatively large amount of capital is needed for this business (compared with many other start-ups), however, it is also scalable on a completely different level. How much a start-up in dentistry is worth, can be seen with Align Technology, valued at over 13 billion US$.


B) Frequently asked questions about the REPLICATE System

B1 How much does a 3D radiograph cost?

A 3D image is becoming increasingly standardized in implantology and costs between 150 and 200 euro.


B2  The jawbone is often inflamed after the removal of the tooth, is that a problem?

In most cases, the damaged tooth is also the source of the infection. At the removal of each tooth, the rotten tissue is removed and an antibiotic or an anti-inflammatory analgesic is prescribed. This means that the patient is well taken care of afterwards. The body can usually deal with the rest on its own. Complications are very rare and have nothing to do with the REPLICATE System. If the physician prescribes the REPLICATE System, he can also prescribe an antibiotic or an anti-inflammatory analgesic. The situation would then be "under control" before the tooth is even removed. After the removal of the damaged tooth, the REPLICATE tooth is then inserted. The new tooth fills the extraction wound to a large extent, in other words, the amount of healing that is required is significantly reduced. If at this time, the doctor is concerned about inserting the REPLICATE tooth immediately into the wound, he or she can still do so within a period of up to three weeks, with very low risk of any complications. Inflammation of the adjacent teeth or other major problems should be treated prior to each implant.


B3 Are the dental laboratories displaced by REPLICATE teeth?

On the contrary, through the REPLICATE System, the dentist can perform significantly more treatments. The dental laboratories are put to even better use. The reason for this is that the dental labs produce the final crown, but not the implant itself. The REPLICATE System, in turn, is delivered without a final crown. This results in positive effects in regards to synergy with dental labs.


B4 I am a patient and want a REPLICATE tooth now, what do I have to do to get one?

Write us an email at and we'll find a solution for you.


B5 I am a dentist and I am still somewhat skeptical. Do you have some more information for me?

Naturally. We are more than happy to send you some more detailed information so that we can convince you of the value of our product. Just write a short e-mail to


We hope we have answered your questions with this update. If you would like to have more specific information on certain topics or have other questions entirely, we look forward to new comments on our site as well as e-mails sent to


Best regards,

Your NDI-Team

Lea and Rüdger


Only registered Companists can comment. Please log in to leave a comment.


Investments in startups and growth companies offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, investments in startups or growth companies are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by diversifying the amount they invest in startups and growth companies and not investing the entire amount in one startup or growth company. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the investors on Companisto are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the investors (Companists) – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, investments in startups and growth companies are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 3,500,000

Invested ( € 1M co-invested )



3.23 %

Share Offered

Please note
The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:

Toll-free phone number for investors calling from Germany:
0800 - 100 267 0

Companisto investors hotline:
+49(0)30 - 346 491 493

We are available Monday through Friday between 9 a.m. – 6 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support
Please register in order to see the complete profile of REPLICATE® System.
Already registered?    Log in